Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient

Details

Serval ID
serval:BIB_C9735292E9B9
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Title
Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient
Journal
Int J Infect Dis
Author(s)
Andrey D. O., Kaiser L., Emonet S., Erard V., Chalandon Y., van Delden C.
ISSN
1878-3511 (Electronic)
ISSN-L
1201-9712
Publication state
Published
Issued date
02/2017
Volume
55
Pages
24-26
Language
english
Notes
Andrey, Diego O
Kaiser, Laurent
Emonet, Stephane
Erard, Veronique
Chalandon, Yves
van Delden, Christian
eng
Case Reports
Canada
Int J Infect Dis. 2017 Feb;55:24-26. doi: 10.1016/j.ijid.2016.12.014. Epub 2016 Dec 14.
Abstract
Mucormycosis (zygomycosis) is an emerging fungal disease in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. A 30-year-old woman diagnosed with acute myelomonocytic leukemia and needing allo-HSCT presented pulmonary and cerebral infection due to Rhizomucor pusillus. This fungal infection was treated with surgical treatment and posaconazole delayed-release tablets. This strategy allowed reaching high drug levels that could not be obtained with the posaconazole solution.
Keywords
Adult, Antifungal Agents/*therapeutic use, Delayed-Action Preparations, Fatal Outcome, Female, Humans, Immunocompromised Host, Leukemia, Myelomonocytic, Acute/immunology/*surgery, Mucormycosis/diagnosis/*drug therapy/immunology/*microbiology, Rhizomucor/drug effects, *Stem Cell Transplantation, Tablets, Transplantation, Homologous, Triazoles/*therapeutic use, Mucormycosis, Posaconazole delayed-release tablets, Rhizomucor pusillus, Zygomycosis
Pubmed
Create date
25/02/2022 16:43
Last modification date
26/02/2022 7:35
Usage data